223 related articles for article (PubMed ID: 34649203)
1. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B
Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203
[TBL] [Abstract][Full Text] [Related]
2. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.
Zahra E; Chen R; Nielsen S; Tran AD; Santo T; Degenhardt L; Farrell M; Byrne J; Ali R; Larance B
Drug Alcohol Rev; 2022 May; 41(4):841-850. PubMed ID: 35130368
[TBL] [Abstract][Full Text] [Related]
3. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
[TBL] [Abstract][Full Text] [Related]
4. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
5. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
[TBL] [Abstract][Full Text] [Related]
6. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
7. Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20.
Nosyk B; Kurz M; Guerra-Alejos BC; Piske M; Dale L; Min JE
Addiction; 2023 Jul; 118(7):1376-1380. PubMed ID: 36772838
[TBL] [Abstract][Full Text] [Related]
8. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
Winstock AR; Lea T; Sheridan J
Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
[TBL] [Abstract][Full Text] [Related]
9. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
11. Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.
Bharat C; Chidwick K; Gisev N; Farrell M; Ali R; Degenhardt L
Int J Drug Policy; 2024 Jan; 123():104255. PubMed ID: 38029481
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
[TBL] [Abstract][Full Text] [Related]
13. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
14. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
15. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
[TBL] [Abstract][Full Text] [Related]
16. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
17. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
Ling R; White B; Roberts J; Cretikos M; Howard MV; Haber PS; Lintzeris N; Reeves P; Dunlop AJ; Searles A
BMC Health Serv Res; 2022 Nov; 22(1):1326. PubMed ID: 36348369
[TBL] [Abstract][Full Text] [Related]
18. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.
Socías ME; Wood E; Lake S; Nolan S; Fairbairn N; Hayashi K; Shulha HP; Liu S; Kerr T; Milloy MJ
Addiction; 2018 Dec; 113(12):2250-2258. PubMed ID: 30238568
[TBL] [Abstract][Full Text] [Related]
19. The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Piske M; Zhou H; Min JE; Hongdilokkul N; Pearce LA; Homayra F; Socias ME; McGowan G; Nosyk B
Addiction; 2020 Aug; 115(8):1482-1493. PubMed ID: 31899565
[TBL] [Abstract][Full Text] [Related]
20. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]